利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.031 秒)

    Aryl substituted 1,4-diazepanes and method of use thereof
    1.
    发明授权
    Aryl substituted 1,4-diazepanes and method of use thereof 失效
    芳基取代的1,4-二氮杂环庚烷及其使用方法

    公开(公告)号：US06667303B1

    公开(公告)日：2003-12-23

    申请号：US10208561

    申请日：2002-07-30

    申请人： Yansong Gu ,  Jeffrey Claude Pelletier

    发明人： Yansong Gu ,  Jeffrey Claude Pelletier

    IPC分类号： C07D24308

    CPC分类号： C07D403/04 ,  C07D243/08 ,  C07D417/04

    摘要： Aryl substituted 1,4-diazepanes are provided such as derivatives of 6-(1,4-diazepan-1-yl)benzo[cd]indol-2(1H)-one, 6-(1,4-diazepan-1-yl)acenaphthylen-1(2H)-one and 5-(1,4-diazepan-1-yl)-2H-naphtho[1,8-cd]isothiazole-1,1-dioxide. Also provided are pharmaceutical compositions containing one or more of the aryl substituted 1,4-diazepanes. The aryl substituted 1,4-diazepanes are useful for treating disorders or deficiencies associated with the 5-HT2C receptor.

    摘要翻译： 提供了芳基取代的1,4-二氮杂环丁烷，例如6-（1,4-二氮杂环庚烷-1-基）苯并[cd]吲哚-2（1H） - 酮，6-（1,4-二氮杂环庚烷-1-基） （2H） - 酮和5-（1,4-二氮杂环庚烷-1-基）-2H-萘并[1,8-cd]异噻唑-1,1-二氧化物。 还提供含有一个或多个芳基取代的1,4-二氮杂环庚烷的药物组合物。 芳基取代的1,4-二氮杂环庚烷可用于治疗与5-HT 2C受体相关的病症或缺陷。

    BIOREACTOR FOR ENGINEERED TISSUE
    4.
    发明申请
    BIOREACTOR FOR ENGINEERED TISSUE 有权
    工程组织生物反应器

    公开(公告)号：US20120288911A1

    公开(公告)日：2012-11-15

    申请号：US13394471

    申请日：2011-05-12

    申请人： Marvi A. Matos ,  William B. Carlson ,  Ivan Vesely ,  Yansong Gu

    发明人： Marvi A. Matos ,  William B. Carlson ,  Ivan Vesely ,  Yansong Gu

    IPC分类号： C12N11/00 ,  B01J19/18

    CPC分类号： C12M25/16 ,  C12M21/08 ,  C12M33/00

    摘要： A system for generating a tissue construct includes a mixing chamber, a piston chamber, a reaction chamber, and a pump. The mixing chamber is configured to receive a hydrogel solution and a cell suspension solution. The piston chamber includes a first piston and is configured to receive a mixture of the hydrogel solution and the cell suspension solution from the mixing chamber. The first piston is configured to push the mixture through one or more capillaries into the reaction chamber. The reaction is configured to receive the mixture and a cross-linking initiator. The pump is configured to move the mixture through the reaction chamber such that the mixture and the cross-linking initiator combine to form an encapsulated cell material.

    摘要翻译： 用于产生组织结构的系统包括混合室，活塞室，反应室和泵。 混合室构造成接收水凝胶溶液和细胞悬液。 活塞室包括第一活塞并且构造成从混合室接收水凝胶溶液和细胞悬浮液的混合物。 第一活塞构造成将混合物推动通过一个或多个毛细管进入反应室。 该反应被配置为接收混合物和交联引发剂。 泵被配置为使混合物移动通过反应室，使得混合物和交联引发剂结合形成封装的细胞材料。

    Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    10.
    发明授权
    Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors 失效

    公开(公告)号：US5977408A

    公开(公告)日：1999-11-02

    申请号：US944189

    申请日：1997-10-06

    申请人： Jeremy Ian Levin ,  Arie Zask ,  Yansong Gu

    发明人： Jeremy Ian Levin ,  Arie Zask ,  Yansong Gu

    IPC分类号： C07C311/29

    CPC分类号： C07C311/29 ,  C07C2101/14

    摘要： The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization.The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by the formula ##STR1## where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A where:A is a 5 to 7 membered, monocyclic, non-aromatic heterocyclic ring having from 1 to 2 heteroatoms independently selected from N, O, and S, optionally substituted by R.sup.1, R.sup.2, R.sup.3 and R.sup.4 ; a --C.sub.3 -C.sub.7 -cycloalkyl containing 0-2 double bonds and optionally substituted with R.sup.1, R.sup.2, R.sup.3 and R.sup.4 ; or --CHR.sup.5 .dbd.CHR.sup.6 --;and Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are described in the specification,and the pharmaceutically acceptable salts thereof,and the optical isomers and diastereomers thereof.